[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335980-105":59,"doc-detail-335980-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","non-coding-rna-related-fcgbp-downregulation-in-head-and-neck-squamous-cell-carcinoma-a-novel-biomarker-for-predicting-paclitaxel-resistance-and-immunosuppressive-microenvironment","Non‑coding RNA‑related FCGBP downregulation in head and neck squamous cell carcinoma: a novel biomarker for predicting paclitaxel resistance and immunosuppressive microenvironment","","Head and neck squamous cell carcinoma (HNSC) has poor outcomes largely driven by chemotherapy resistance and an ineffective stratification of patients. This study investigates Fc gamma binding protein (FCGBP), a mucus-associated immune-related protein, whose role in HNSC has remained unclear. Using TCGA and GEO datasets, the expression, survival impact, and correlations with immune infiltration are analyzed with regression and bioinformatics approaches, identifying an ncRNA-related FCGBP axis linked to paclitaxel resistance and immunosuppressive microenvironments.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/non-coding-rna-related-fcgbp-downregulation-in-head-and-neck-squamous-cell-carcinoma-a-novel-biomarker-for-predicting-paclitaxel-resistance-and-immunosuppressive-microenvironment/335980/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/non-coding-rna-related-fcgbp-downregulation-in-head-and-neck-squamous-cell-carcinoma-a-novel-biomarker-for-predicting-paclitaxel-resistance-and-immunosuppressive-microenvironment/335980.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is paclitaxel resistance a major issue in HNSC?","Question",{"text":112,"@type":113},"Chemoresistance, especially to chemotherapy, strongly contributes to poor prognosis in advanced HNSC. Stratified chemotherapy requires reliable biomarkers, but validated options remain limited.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What does the study report about FCGBP in HNSC?",{"text":117,"@type":113},"FCGBP functions as a potential tumor suppressor gene in HNSC. Its expression is negatively correlated with tumor-infiltrating macrophages and with paclitaxel resistance.",{"name":119,"@type":110,"acceptedAnswer":120},"What ncRNA-related pathway is linked to FCGBP regulation?",{"text":121,"@type":113},"The study identifies the PART1/AC007728.2/LINC00885/hsa-miR-877-5p/FCGBP axis as an upstream ncRNA-related pathway potentially involved in FCGBP regulation in HNSC.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335980,1790180004,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":4},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nNon‑coding RNA‑related FCGBP downregulation in head and necksquamous cell carcinoma: a novel biomarker for predicting paclitaxel resistance and immunosuppressive microenvironment  \nQin Ding1,2,3, Fengjie Lin1,2,3, Zongwei Huang1,2, Ying Li1,2, Sunqin Cai1,2, Xin Chen1,2, Hui Liu1,2* & Sufang Qiu1,2*  \nIn head and neck squamous cell carcinoma (HNSC), chemoresistance is a major reason for poor prognosis. Nevertheless, there is a lack of validated biomarkers to screen for patients for categorical chemotherapy. Fc gamma binding protein (FCGBP) is a mucus protein associated with mucosal epithelial cells and has immunological functions that protect against tumors and metastasis. However, the effect of FCGBP on HNSC is unclear. In pan‑cancer tissues, the expression of FCGBP and the survival status of patients were analyzed using information from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) . Correlation analysis and Cox regression analysis were conducted to confirm the relationship and survival outcome. Bioinformatics analysis was utilized to predict the probable upstream non‑coding RNA. FCGBP functioned as a potential tumor suppressor gene in HNSC. Notably, FCGBP expression was negatively correlated with enriched tumor‑infiltrating macrophages and paclitaxel resistance. Cox regression with gene, clinical, and immune factors showed that FCGBP was a risk factor acting in an independent manner. In HNSC, the utmost possibly upstream non‑coding RNA‑related pathway of FCGBP was also discovered to be the PART1/AC007728.2/LINC00885/hsa‑miR‑877‑5p/FCGBP axis. According to the present study, non‑ coding RNA‑related low levels of FCGBP are a prognostic indicator and are linked to an HNSC‑related immunosuppressive state.  \nKeywords Fc gamma binding protein, Paclitaxel resistance, Immune infiltration, Targeted therapy, Head and neck cancer  \nAs the seventh most common prevalent cancer worldwide, head and neck cancers are mainly composed ofsquamous cell carcinomas1,2. Most (> 50%) of head and neck squamous cell carcinoma (HNSC) show a local progression or distant metastasis3. Irrespective of multiple therapeutic approaches, the results for advanced HNSC patients’ are not encouraging; with 40–60% of patients experiencing local progression or recurrence anda poor prognosis4. The resistance to treatment, particularly to chemotherapy, is an overwhelming factor in poor prognosis1,5. Thus, for stratified chemotherapy and prognosis, there is an urgent need to identify viable biomarkers as well as new therapeutic targets for effectively managing HNSC.  \nA mucin called Fc gamma binding protein (FCGBP) was first discovered in the intestinal epithelium and encodes a cysteine-rich glycoprotein6. It is a key factor in the protection of innate mucosal epithelium, tumor immunity, and tumor metastasis7. The expression of FCGBP varies across tissues, which has been linked to tumorigenesis in many malignancies8–14. Besides, the FCGBP level was one of the top differentially expressed transcripts between chemosensitive and chemoresistant tissues15.  \n1Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China. 2Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China. 3These authors contributed equally: Qin Ding and Fengjie Lin. *email: [liuhuifj@sina.com](liuhuifj@sina.com); [sufangqiu@fjmu.edu.cn](sufangqiu@fjmu.edu.cn)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nHowever, few reports have been dedicated to the chemotherapeutic effects ofFCGBP on the tumor. Lin YHet al. reported FCGBP as a potential biomarker to predict HNSC prognosis16. These findings prompted us to delve into the expression, prognosis, and possible mechanisms ofFCGBP in HNSC. Furthermore, even though FCGBP is confirmed to have a positive link to immune cells, the assoc","cbCaihZ0UYbKccnr","https://ap.wps.com/l/cbCaihZ0UYbKccnr","pdf",11862689,16,"English","# Introduction\n## FCGBP background and rationale\n# Materials and methods\n## Data pre-processing\n## Immunohistochemistry analysis","[{\"question\":\"Why is paclitaxel resistance a major issue in HNSC?\",\"answer\":\"Chemoresistance, especially to chemotherapy, strongly contributes to poor prognosis in advanced HNSC. Stratified chemotherapy requires reliable biomarkers, but validated options remain limited.\"},{\"question\":\"What does the study report about FCGBP in HNSC?\",\"answer\":\"FCGBP functions as a potential tumor suppressor gene in HNSC. Its expression is negatively correlated with tumor-infiltrating macrophages and with paclitaxel resistance.\"},{\"question\":\"What ncRNA-related pathway is linked to FCGBP regulation?\",\"answer\":\"The study identifies the PART1/AC007728.2/LINC00885/hsa-miR-877-5p/FCGBP axis as an upstream ncRNA-related pathway potentially involved in FCGBP regulation in HNSC.\"}]","Non‑coding RNA‑related FCGBP downregulation in head and neck squamous cell carcinoma: a novel biomarker for predicting paclitaxel resistance and immunosuppressive microenvironment | PDF",1790013030]